Table 3 Demographic and clinical characteristics of ADHD subjects according to genotypes of the -3081(A/T) polymorphism
| Â | ADHD subjects with A/A genotype | ADHD subjects with A/T + T/T genotypes | p-value |
|---|---|---|---|
Age in yr, mean (SD) | 9.0 (2.4) | 9.1 (2.0) | 0.81 |
Sex (M/F) | 22/7 | 70/13 | 0.31 |
IQ, mean (SD) | 107.2 (13.3) | 107.5 (14.0) | 0.92 |
ADHD subtypes | Â | Â | 0.35 |
   Combined | 58.6% | 62.7% |  |
   Inattentive | 34.5% | 22.9% |  |
   Hyperactive-impulsive | 0.0% | 7.2% |  |
   NOS | 6.9% | 7.2% |  |
Comorbidity | Â | Â | Â |
   Oppositional defiant disorder | 6.9% | 15.7% | 0.19 |
   Anxiety disorder | 3.4% | 13.3% | 0.13 |
   Enuresis | 13.8% | 1.2% | 0.02 |
ARS baseline scores, mean (SD) | Â | Â | Â |
   Total | 23.9 (11.4) | 27.9 (9.7) | 0.08 |
   Inattentive | 13.6 (6.3) | 15.6 (5.6) | 0.12 |
   Hyperactivity/impulsivity | 10.3 (6.9) | 12.3 (5.7) | 0.14 |
Dosage of MPH (mg/day), mean (SD) | Â | Â | Â |
   Baseline dose | 19.7 (9.3) | 20.0 (8.0) | 0.88 |
   Final 2 weeks dose | 27.9 (11.1) | 29.7 (11.8) | 0.48 |
CGI-I score, mean (SD) | 2.8 (0.9) | 2.4 (0.8) | 0.04 |